Medicine and Dentistry
Barrett Esophagus
100%
Esophageal Adenocarcinoma
52%
Malignant Neoplasm
38%
Esophagus
38%
Neoplasm
35%
Adenocarcinoma
34%
Diseases
33%
Dysplasia
32%
Surgery
31%
Gastroesophageal Reflux
24%
Cohort Analysis
19%
COVID-19
19%
Risk Stratification
17%
Endoscopy
17%
Intestinal Metaplasia
16%
Symptom
14%
Survival Rate
13%
Endoscopic Surgery
13%
Stomach Adenocarcinoma
11%
Overall Survival
11%
Patient Experience
10%
Patient-Reported Outcome
10%
Neoadjuvant Therapy
10%
Chronic Disease
10%
Esophagus Tumor
10%
Cell Cycle
9%
Primary Biliary Cirrhosis
9%
Pelvic Radiotherapy
9%
Esophageal Adenocarcinoma Cell Line
9%
Patient Referral
9%
Gut
9%
Transcription Factors
9%
Stomach Cancer
9%
Tumor Regression
9%
Learning Curve
9%
Signet Ring Cell
9%
Surgical Risk
9%
Retrospective Cohort Study
9%
Esophageal Dilatation
9%
Acute Cholecystitis
9%
Remote Patient Monitoring
9%
Bariatric Surgery
9%
Scoring System
9%
Ciclonicate
9%
End Stage Liver Disease
9%
Skeletal Muscle
9%
Toxicity
9%
Outpatient
9%
Biological Marker
9%
Rhythm
9%
Biochemistry, Genetics and Molecular Biology
Esophagus
64%
FOXM1
28%
Exome
19%
Cancer Cell
14%
Transcription Factors
14%
Precursor
12%
Metaplasia
11%
Whole Genome Sequencing
9%
Gene Network
9%
PLK1
9%
Ursodeoxycholic Acid
9%
ETV4
9%
SARS Coronavirus
9%
RNA Sequence
9%
Polo-Like Kinase
9%
KLF5
9%
Nomenclature
9%
Patient Registry
9%
Tissue Factor
9%
GATA4
9%
PIM2
9%
Oncogene
9%
Tumor Gene
9%
Gene Expression
8%
Radiofrequency
8%
ATAC-Seq
8%
Leukocyte
6%
Survival Rate
6%
Normal Human
5%
Nursing and Health Professions
Barrett Esophagus
48%
Disease
17%
Quality of Life
12%
Practice Guideline
10%
Patient-Reported Outcome
10%
Clinical Practice
10%
Malignant Neoplasm
10%
Muscle Mass
9%
Clinical Outcome
9%
Esophagus Dilatation
9%
Functional Status
9%
Gastrointestinal Disease
9%
Symptom
6%
Length of Stay
6%
Nutritional Status
6%
Hospital Readmission
6%
Chronic Disease
6%
Gastroesophageal Reflux
5%
Endoscopy
5%
